A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects

NCT06449703 · Recruiting

Last updated 2026-05-28

This trial tested a single dose of the combination medication insulin degludec/liraglutide in healthy Chinese adults to measure how the drug is absorbed and processed in the body.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 44 people Planned (estimated).

Who can join Ages 18–45 · all sexes Healthy volunteers accepted.

Timeline Started 2024-05 · est. completion 2024-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06449703 ↗

Description as written by the study sponsor.

The main purpose of the trial is to compare the pharmacokinetics of insulin degludec and liraglutide as part of a combination product insulin degludec/liraglutide compared with Xultophy®. During the trial period, serials of blood samples will be collected from the participants at two dosing periods, in order to determine the concentration of insulin degludec and liraglutide. The total volume of blood taken throughout the whole trial period will be less than 400 mL. Participants will be asked to stay on daytime and overnight in the trial sites on some predefined days. For other outpatient days, participants need to attend the trial site as required for drug administration or required assessments.

Treatments tested

insulin degludec/liraglutide Drug

Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the abdomen.
Xultophy® Drug

Xultophy®

Main thing measured	Maximum observed plasma insulin degludec concentration
Sponsor	Tonghua Dongbao Pharmaceutical Co.,Ltd
Conditions studied	Healthy
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06449703 ↗